Summary
- Kiromic BioPharma has filed to raise $20 million in a U.S. IPO, although the final figure may differ.
- The firm is advancing programs for the treatment of lymphomas and solid tumors.
- KRBP is still a very early stage biopharma and would present very high risk for individual investors.
- Looking for more stock ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
Kiromic BioPharma (KRBP) has filed to raise $20 million in an IPO of its common stock, according to an S-1 registration statement.
The company uses a proprietary machine-learning enhanced platform to target promising compounds for the treatment of lymphomas and solid tumors.
KRBP is an extremely early stage biopharma firm with a resulting long-term and high risk profile.
I'll provide an update when we learn more IPO details from management.
Company & Technology
Houston, Texas-based Kiromic was founded to advance a pipeline of drug candidates to treat various lymphomas and solid tumors.
Management is headed by Chairman and CEO Maurizio Internati, DBSc, PhD., who has been with the firm since 2012 and was previously an associate professor at the MD Anderson Cancer Center in Houston, Texas.
